Description
Contradictory evidence shows TREM2 can both protect against and worsen tau pathology. The molecular determinants of these opposing outcomes are unresolved, preventing rational therapeutic design.
Source: Debate session sess_SDA-2026-04-03-gap-tau-prop-20260402003221 (Analysis: SDA-2026-04-03-gap-tau-prop-20260402003221)
Resolution criteria
Resolution requires: (1) systematic comparison of TREM2 agonist effects (ATV-TREM2 or TREM2 agonistic antibodies) in at least two tau pathology mouse models (P301S vs rTg4510) with head-to-head experimental design, measuring tau pathology (AT8 IHC), microglial activation (Iba1), and cognitive outcomes; (2) single-cell RNA-seq of microglia from both models after TREM2 treatment identifying model-specific vs common response programs; (3) human iPSC-derived microglia/xenograft experiments comparing TREM2 responses across different AD genetic backgrounds. Single-model studies cannot resolve context-dependency of TREM2 effects.
Evidence summary
Resolved by hypothesis h-var-08a4d5c07a: Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration. Score: 0.907. Supporting PMIDs: 33875891, 30610225, 31748742, 27519954, 33741860.